Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms

SYNAPSING

Disrupted neuronal connectivity and synapse dysfunction can manifest clinically as a range of emotional, behavioural and cognitive symptoms that are common to, and often overlapping in, mental disorders (MDs) such as major depressive disorder, bipolar disorder and schizophrenia and neurodegenerative disorders (NDs) such as Alzheimers disease and...

Funding Programme
Start Date
End Date
Total Funding
€ 6 999 921
European Countries Involved

Synaptic circuit protection in Alzheimers’s disease (AD) and Huntingtion’s disease (HD): BDNF/TrkB and Arc signaling as rescue factors

CircProt

Alzheimer´s (AD) and Huntington´s disease (HD) result from the erroneous communication of neurons at synapses in different brain areas (neocortex, hippocampus, striatum). The protein BDNF regulates synaptic communication under healthy conditions. However, insufficient release of BDNF from neurons and defective BDNF signaling in target neurons...

Funding Programme
Start Date
End Date
European Countries Involved

Synaptic Dysfunction in Alzheimer Disease

SyDAD

Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programmes from several big pharmaceutical companies. Increased collaboration between...

Funding Programme
Start Date
End Date
Total Funding
€ 3 846 736
European Countries Involved

Synaptic dysfunction in Neurodegenerative Diseases

SYNDEGEN

Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a main focus of research, increasing evidence points to synapses as the site where Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) begin. There is growing evidence that synapses are...

Funding Programme
Start Date
End Date
Total Funding
€ 3 129 428
European Countries Involved

Tandem Repeats Associated with Neurogenomic Somatic Instability and Neurodegeneration

TRANSIT-ND

"Dementia and other neurodegenerative diseases are among the leading causes of disability worldwide and have an immense societal impact due to lack of effective treatments. For developing better preventive and therapeutic strategies, it is essential to clarify their still largely elusive genetic basis and pathophysiology. Emerging insights from the...

Funding Programme
Start Date
End Date
Total Funding
€ 1 495 557
European Countries Involved

Targeted small-molecule Stabilisation of Protein-Protein Interactions

TASPPI

The goal of the TASPPI European Training Network (ETN) is the establishment of a highly interdisciplinary research and educational training platform for early stage scientists in the Chemical Life Sciences to overcome the inherent boundaries between academia and industry and to increase their employability in both areas. To this end we have teamed...

Funding Programme
Start Date
End Date
Total Funding
€ 3 342 323
European Countries Involved

Targeting Circadian Clock Dysfunction in Alzheimer’s Disease

TClock4AD

Recent Nobel Prize-winning discoveries on circadian clock (CC) have laid the foundation for ground-breaking approaches to treat many diseases, including Alzheimer’s disease (AD). AD is a current public health priority. Amplifying the demographic burden of the rising numbers of patients is the low success rate of AD therapies. Given that CC genes...

Funding Programme
Start Date
End Date
Total Funding
€ 3 811 636

Targeting epigenetic dysregulation in the brainstem in Alzheimer’s disease

EPI-AD

We aim to elucidate the exact role of epigenetic dysregulation in the brainstem in the pathogenesis of AD. For this purpose, we will examine post-mortem brainstem tissue derived from AD patients, and matched controls, for epigenetic differences. By investigating AD-specific epigenetic profiles in the blood of individuals suffering from Mild...

Funding Programme
Start Date
End Date
European Countries Involved

Targeting the propagation of pathogenic protein assemblies in neurodegenerative disease

NeuTARGETS

Similar to prion diseases, more common fatal neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease are linked to the aggregation of different proteins (including Tau, Abeta and alpha- synuclein in the brain of affected patients. Furthermore most of the resulting brain lesions initially appear in specific brain areas and the...

Funding Programme
Start Date
End Date
Total Funding
€ 1 369 544
European Countries Involved

Tau, a molecular modulator of neuronal energy managment

EnergizeTau

"The intraneuronal somatodendritic ""missorting"" and aggregation of Tau are pathological hallmarks in neurodegenerative diseases (NDDs) like and Alzheimer's disease (AD), and are thought to be drivers of neurotoxicity. That NDDs manifesting with Tau ""missorting"" present with (neuro)metabolic abnormalities, often prior to pathology onset, is...

Funding Programme
Start Date
End Date
Total Funding
€ 2 194 940
European Countries Involved

The chemistry and physics of RNP granules: how they form, age and cause disease

PhaseAge

Recent studies suggest that defective ribonucleoprotein (RNP) granules and altered RNA processing cause neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). However, defective RNP granules only develop late in life, suggesting that young cells have mechanisms in place to prevent their...

Funding Programme
Start Date
End Date
Total Funding
€ 1 931 303
European Countries Involved

The effects of an extensive exercise program on the progression of mild cognitive impairment (MCI)

NEUROEXERCICE

Epidemiological studies have shown that leisure-time physical activity at midlife is associated with a decreased risk of dementia later in life. Although initial studies indicate enhanced behavioural performance in dementia patients after three months of exercise, little is known about the effect of an extensive, controlled and regular exercise...

Funding Programme
Start Date
End Date
Total Funding
€ 1 395 100
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).